In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin
- 1 July 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (7) , 2362-2365
- https://doi.org/10.1128/aac.47.7.2362-2365.2003
Abstract
Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.Keywords
This publication has 30 references indexed in Scilit:
- Antimicrobial Susceptibilities of Diverse Bacillus anthracis IsolatesAntimicrobial Agents and Chemotherapy, 2002
- The prophylaxis and treatment of anthraxPublished by Elsevier ,2002
- Antibiotic Susceptibilities of 96 Isolates of Bacillus anthracis Isolated in France between 1994 and 2000Antimicrobial Agents and Chemotherapy, 2002
- Anthrax as a Biological Weapon, 2002JAMA, 2002
- Molecular Analysis of Rifampin Resistance in Bacillus anthracis and Bacillus cereusAntimicrobial Agents and Chemotherapy, 2002
- Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2001
- Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998Drugs, 1999
- Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporterAntimicrobial Agents and Chemotherapy, 1993
- The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA proteinAntimicrobial Agents and Chemotherapy, 1992